TRIN Pharma names Stefan Wohlfeil CEO

TRIN Pharma GmbH has appointed Stefan Wohlfeil as to be the company's new CEO. Release

RXi Pharmaceuticals has announced that Noah D. Beerman has joined the company as its new President and CEO. Release

Amarin Corporation has announced the appointment of John F. Thero as its CFO. Release

UCB announced the appointment of Ismail Kola, Executive Vice President, UCB & President of UCB New Medicines, UCB's discovery research through to 'proof of concept' organization. Ismail Kola will join UCB's Executive Committee November 23, 2009. Release

International Stem Cell Corporation has made changes to its management team. The company's current Board Member and Executive Vice-President, Andrey Semechkin, will become CEO on November 15, 2009, and Brian Lundstrom has joined the company as President. Release

ExonHit Therapeutics has tapped Hervé Duchesne de Lamotte to be the company's CFO. Release

TARIS Biomedical has tapped Julie Lekstrom Himes, to serve as CMO. Release

Gentium has appointed Khalid Islam as Interim CEO on a temporary and part-time basis. Release

Bernard R. Tyrrell to be EpiCept Corporation's Senior Vice President, Sales and Marketing--a newly created position. Release

InterMune announced several additions to its leadership team: Terri Shoemaker will be vice president of sales; Erik Harris will be vice president of marketing; Darren Cline will serve as Vice President of Managed Care and Access; and Giacomo di Nepi has been appointed to the newly created position of Senior Vice President and General Manager, Europe. Release

Ahead of potential Qutenza launch, NeurogesX names Timothy Arendt as Vice President, Sales; Amy C. Cavers as Senior Director of Marketing; and Linda L. Schock as Director of Commercial Operations. Release

Tim Rothwell has been appointed to Emisphere Technologies' board. Release

Dynavax Technologies Corporation has named Francis R. Cano to join the Board of Directors. Release

Cipher Pharmaceuticals names William Claypool to its Board of Directors. Release

Arrowhead Research Corporation announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc., has appointed Mostafa Analoui and Bruce D. Given to its Board of Directors. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.